(Bloomberg) Paulson & Co., the firm led by billionaire John Paulson, tripled its stakes in Endo International Plc and Akorn Inc. in the first quarter, sticking to big-name health-care wagers even as many other hedge funds ran the opposite way.
The firm increased its stake in Endo by 6.22 million shares, bringing the value of its holding to $268 million as of March 31, according to a filing Monday with the U.S. Securities and Exchange Commission. Brahman Capital, Soros Fund Management and Blue Ridge Capital sold out of their stakes. The drugmaker, led by former Valeant Pharmaceuticals International Inc. executive Rajiv De Silva, has faced scrutiny over its use of acquisitions and leverage to grow.
